Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06929325 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Name: Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors — clinical trial record (NCT06929325)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 3

SponsorCSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Started2025-04

View on ClinicalTrials.gov ↗

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

42 trials monitored

See 1 trial at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

A randomized, double-blind, multicenter phase III clinical study to evaluate the efficacy and safety of sirolimus for injection (albumin-bound) combined with fulvestrant in patients with HR+ and HER2- advanced breast cancer.

Trial Details

NCT Number	NCT06929325
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	HR+/HER2- Advanced/Metastatic Breast Cancer
Enrollment	312 participants
Start Date	2025-04
Primary Completion	2026-10 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-04-16